A statement released earlier today by H.C. Wainwright about Ligand Pharma (NASDAQ:LGND) bumps the target price to $160.00
- Updated: October 4, 2016
H.C. Wainwright bumped up the target of Ligand Pharma (NASDAQ:LGND) to $160.00 stating a potential upside of 0.59%.
Boasting a price of $100.57, Ligand Pharma (NASDAQ:LGND) traded -1.22% lower on the day. With the last stock price close down -14.20% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Ligand Pharma has recorded a 50-day average of $108.75 and a two hundred day average of $117.22. Volume of trade was down over the average, with 233,016 shares of LGND changing hands under the typical 441,734
With a total market value of $0, Ligand Pharma has price-earnings ratio of 9.48 with a one year low of $82.06 and a one year high of $139.79 .
A total of 6 equity analysts have released a ratings update on LGND. zero firms rating the stock a strong buy, 3 firms rating the stock a buy, 2 firms rating the stock a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $130.33.
More About Ligand Pharma (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.